logo-loader
ReNeuron Group PLC

ReNeuron jumps at opening bell as it gets green light to begin second part of phase I/II eye disease trial

Data from the phase II part of the phase I/II trial is expected in the second half of 2018, with readouts from the subsequent, larger phase IIb study due in 2020

eye
ReNeuron will use the new formulation of its hRPC therapy in the phase II trial

The ongoing phase I/II trial of ReNeuron Group Plc’s (LON:RENE) human retinal progenitor cell (hRPC) therapy has been given the green light by regulators to move into the phase II part of the study.

The hRPC therapy candidate is being trialled in patients with retinitis pigmentosa – a rare degenerative eye disease which can lead to blindness.

READ: ReNeuron making good progress with all of its key therapeutic programmes

The Data Safety Monitoring board gave its approval following short-term data from the nine patients taking part in the study, which indicated the therapy was safe and well-tolerated at the three doses tested.

ReNeuron has been hard at work developing a new formulation of hRPC recently which can be cryopreserved (frozen), extending its shelf life and allowing it to be shipped anywhere around the globe.

Cryopreserved formulation to be used in phase II trial

The final high-dose cohort patients in the phase I part of the study was treated with this new formulation, and the company expects to this version in the phase II element of the study.

This part of the trial will recruit six patients whose diseases haven’t progressed as much as those in the phase I element.

Readouts from the phase II trial are expected in the second half of next year, with efficacy data from a subsequent, larger phase IIb study due in 2020.

ReNeuron confirmed once again that an application will also be filed later this year to test the same hRPC therapy in a phase II trial in cone-rod dystrophy patients, and it hopes to have both phase II trials (RP and CRD) running concurrently.

‘High commercial potential’

"We are delighted that the Data Safety Monitoring Board has given its approval to progress our ongoing clinical trial in retinitis pigmentosa into its Phase II element,” said chief executive Olav Hellebø.

“Our hRPC cell therapy candidate offers the potential for an entirely new therapeutic option for patients suffering from diseases of the retina such as retinitis pigmentosa and cone-rod dystrophy, and represents a therapeutic platform technology with high commercial potential for ReNeuron.”

Shares rose 7.3% to 2.05p at the opening bell on Wednesday.

Quick facts: ReNeuron Group PLC

Price: £2.05

Market: LSE
Market Cap: £65.26 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ReNeuron Group PLC named herein, including the promotion by the Company of ReNeuron Group PLC in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Investor Update: Asiamet signs agreement with China Nonferrous Metals

Headlines from the Proactive UK newsroom. Asiamet (LON:ARS) has teamed up with China Nonferrous Metals to carry out an engineering evaluation on the BKM Copper project in Indonesia.  China NFC is currently building a zinc mine in Sumatra and is looking to expand its activities in the...

4 weeks, 1 day ago

2 min read